LS Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

LS Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-113	Closed	-$12K	–	1641
2020 Q1	$12K	Sell	113 -620	-85%	-$71.6K	﹤0.01%	1496
2019 Q4	$84K	Buy	733 +36	+5%	+$3.59K	﹤0.01%	1166
2019 Q3	$56K	Hold	697	–	–	﹤0.01%	1272
2019 Q2	$51K	Hold	697	–	–	﹤0.01%	1298
2019 Q1	$65K	Hold	697	–	–	﹤0.01%	1231
2018 Q4	$51K	Hold	697	–	–	﹤0.01%	1264
2018 Q3	$61K	Hold	697	–	–	﹤0.01%	1262
2018 Q2	$69K	Hold	697	–	–	﹤0.01%	1224
2018 Q1	$83K	Hold	697	–	–	﹤0.01%	1162
2017 Q4	$89K	Buy	+697	New	+$87.6K	0.01%	1162
2016 Q4	–	Sell	-1,208	Closed	-$82K	–	1866
2016 Q3	$82K	Sell	1,208 -340	-22%	-$24K	0.01%	1061
2016 Q2	$86K	Buy	1,548 +238	+18%	+$15K	0.01%	1041
2016 Q1	$82K	Buy	1,310 +347	+36%	+$23.1K	0.01%	955
2015 Q4	$91K	Hold	963	–	–	0.01%	893
2015 Q3	$77K	Hold	963	–	–	0.01%	958
2015 Q2	$115K	Buy	+963	New	+$115K	0.01%	829

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

LS Investment Advisors's ALNY Position: Q2 2020 in Review

LS Investment Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 113 shares — an estimated $12K sold.

LS Investment Advisors first reported a position in ALNY in Q2 2015 and held it in 16 quarters. The position peaked at $115K in Q2 2015. 375 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

LS Investment Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
LS Investment Advisors sold 113 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $12K.
LS Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 16 quarters.
LS Investment Advisors's Alnylam Pharmaceuticals position peaked at $115K in Q2 2015.
375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on LS Investment Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.